These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31673415)

  • 1. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
    RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
    Burmester GR; Lin Y; Patel R; van Adelsberg J; Mangan EK; Graham NM; van Hoogstraten H; Bauer D; Ignacio Vargas J; Lee EB
    Ann Rheum Dis; 2017 May; 76(5):840-847. PubMed ID: 27856432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M
    J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement or Worsening of Disease Activity After Switch to Sarilumab in Patients With Rheumatoid Arthritis With a Partial Response to Adalimumab.
    Curtis JR; Aletaha D; Burmester G; Ford K; van Hoogstraten H; Praestgaard A; Bykerk VP;
    J Clin Rheumatol; 2023 Jun; 29(4):196-201. PubMed ID: 36858816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
    Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR
    RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
    Burmester GR; Strand V; Kivitz AJ; Hu CC; Wang S; van Hoogstraten H; Klier GL; Fleischmann R
    Rheumatology (Oxford); 2023 Oct; 62(10):3268-3279. PubMed ID: 36727470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.
    Cohen S; Pablos JL; Pavelka K; Müller GA; Matsumoto A; Kivitz A; Wang H; Krishnan E
    Arthritis Res Ther; 2019 Mar; 21(1):84. PubMed ID: 30922373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Gabay C; Burmester GR; Strand V; Msihid J; Zilberstein M; Kimura T; van Hoogstraten H; Boklage SH; Sadeh J; Graham NMH; Boyapati A
    Arthritis Res Ther; 2020 Apr; 22(1):70. PubMed ID: 32264972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
    Boyapati A; Schwartzman S; Msihid J; Choy E; Genovese MC; Burmester GR; Lam G; Kimura T; Sadeh J; Weinreich DM; Yancopoulos GD; Graham NMH
    Arthritis Rheumatol; 2020 Sep; 72(9):1456-1466. PubMed ID: 32343882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.
    Genovese MC; Braun DK; Erickson JS; Berclaz PY; Banerjee S; Heffernan MP; Carlier H
    J Rheumatol; 2016 Feb; 43(2):289-97. PubMed ID: 26669919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis.
    Alten R; Markland C; Boyce M; Kawakami K; Muniz R; Genovese MC
    Int J Rheum Dis; 2020 Nov; 23(11):1514-1525. PubMed ID: 32852139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors.
    Fleischmann R; Genovese MC; Maslova K; Leher H; Praestgaard A; Burmester GR
    Rheumatology (Oxford); 2021 Nov; 60(11):4991-5001. PubMed ID: 33871596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
    Fleischmann RM; Genovese MC; Enejosa JV; Mysler E; Bessette L; Peterfy C; Durez P; Ostor A; Li Y; Song IH
    Ann Rheum Dis; 2019 Nov; 78(11):1454-1462. PubMed ID: 31362993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.
    Keystone EC; Genovese MC; Schlichting DE; de la Torre I; Beattie SD; Rooney TP; Taylor PC
    J Rheumatol; 2018 Jan; 45(1):14-21. PubMed ID: 28811354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
    Kameda H; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham N; Tanaka Y
    Mod Rheumatol; 2020 Mar; 30(2):239-248. PubMed ID: 31268376
    [No Abstract]   [Full Text] [Related]  

  • 18. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
    Keystone EC; Breedveld FC; van der Heijde D; Landewé R; Florentinus S; Arulmani U; Liu S; Kupper H; Kavanaugh A
    J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
    Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
    Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies.
    Genovese MC; Kellner H; Arai Y; Muniz R; Alten R
    RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.